Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Meletios- Athanasios Dimopoulos, Professor
Therapeutic Clinic Department, Faculty of Medicine. University of Athens
Study ChairKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Department of Clinical Therapeutics, University of Athens School of Medicine, "alexandra" General Hospital
Athens, Greece
- Department of Hematology & Medical Research, 251 General Air Force Hospital
Athens, Greece
- Department of Hematology, "theagenion" Cancer Center
Thessaloniki, Greece
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2009
- Primary completion
- 31 May 2013
- Completion
- 31 May 2013
- Last update posted
- 5 Aug 2014
- Registered enrollment
- 17
- Registry id
- NCT00972959
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.